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Abstract
Presepsin, a glycoprotein produced during bacterial phagocytosis, is used as a sepsis
marker for bacterial infections. However, presepsin levels are affected by renal function,
and the evaluation criteria according to kidney function or in chronic kidney diseases remain
controversial. Furthermore, presepsin may be increased by sample stirring, but no studies
have evaluated this effect.In this study, we excluded the effect of stirring by standardizing
the blood collection conditions, analyzed the influence of kidney function on presepsin con-
centrations, and recalculated the reference range based on the findings. EDTA-whole blood
from 47 healthy subjects and 85 patients with chronic kidney disease was collected to mea-
sure presepsin by PATHFAST. Presepsin was found to be significantly correlated with the
levels of creatinine (r = 0.834), eGFRcreat (r = 0.837), cystatin-C (r = 0.845), and eGFRcys
(r = 0.879). Furthermore, in patients with CKD, presepsin levels stratified by eGFRcys
showed a significant increase in the CKD G2 patient group and with advancing glomerular
filtration rate stage. The following values were obtained: Normal: 97.6 ± 27.4 pg/mL, CKD
G1: 100.2 ± 27.6 pg/mL, CKD G2: 129.7 ± 40.7 pg/mL, CKD G3: 208.1 ± 70.2 pg/mL, CKD
G4: 320.2 ± 170.1 pg/mL, CKD G5: 712.8 ± 336.3 pg/mL. The reference range, calculated
by a nonparametric method using 67 cases of healthy volunteers and patients with chronic
kidney disease G1, was found to be 59–153 pg/mL, which was notably lower than the stan-
dard reference range currently used. Presepsin concentrations were positively correlated
with a few biomarkers of renal function, indicating the necessity to consider the effect of
renal function in patients with renal impairment. Using the recalculated reference range con-
sidering kidney function may improve the accuracy of evaluating presepsin for diagnosis of
sepsis compared to the standard reference currently in use.
Introduction
Presepsin is a protein whose blood concentrations increase specifically during sepsis. Since its
discovery in 2002 in Japan, presepsin has been widely used as a sepsis marker. Membrane-
bound CD14, a surface antigen expressed on the cell membrane of monocyte macrophages
and granulocytes, is a receptor for bacterial lipopolysaccharide (LPS), which activates cells via
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Toll-like receptor 4 [1]. Additionally, soluble CD14 present in the blood induces the activation
of endothelial and epithelial cells without membrane-bound CD14 [2] and plays an important
role in sensing invasion of bacteria in vivo. Recently, it was reported that granulocyte-mediated
bacterial phagocytosis triggers elastase or cathepsin D to proteolytically cleave CD14 to pro-
duce presepsin and release it into the blood [3]. Furthermore, it was shown that the concentra-
tion of presepsin increases with infection in patients with leucopenia [4], indicating that cells
other than monocytes can trigger presepsin production.
Unlike procalcitonin, which is conventionally used for sepsis diagnosis, presepsin responds
very weakly to inflammation such as trauma and burn, and is considered highly specific for
bacterial infection [5–7]. Compared to conventional markers, presepsin is a good clinical indi-
cator that responds well to changes in the disease state and thus reflects the effect of therapeu-
tics on the condition [8–10].
The presepsin cut-off value for sepsis or infectious disease diagnosis is 400–700 pg/mL (500
pg/mL: Japan) [11]. However, as reported by Nagata at el [12], presepsin levels are affected by
renal function; in the blood of patients with renal disorder such as those on dialysis, the con-
centration can be higher, as presepsin is excreted from the kidney. Therefore, it is unsuitable
to use the general cut-off values for diagnosing patients with chronic kidney disease (CKD), as
the false high value associated with renal impairment can lead to erroneous judgment. Further-
more, the measured presepsin levels can be increased by sample stirring, but no studies have
considered this effect, which may result in artificially high values.
In the current study, presepsin levels were measured in patients with CKD and analyzed for
their relationship with the renal function index. Particularly, we focused on the relationship in
early CKD stages. Additionally, by standardizing the blood collection conditions and exclud-




This study enrolled 85 outpatients with CKD who visited the Tokushima University Hospital
from May 2017 to September 2017. All patients were over 18 years of age and had no history of
dialysis or infection symptoms. Infection was diagnosed by the physician based on apparent
clinical manifestations or laboratory results. We confirmed that patients with eGFR>60 mL/
min/1.73 m2 had abnormalities in the kidney structure such as albuminuria, urine sediment
abnormalities, electrolytes, and other abnormalities due to tubular disorders or abnormalities
detected by histology, structural abnormalities detected by imaging, or a history of kidney
transplantation. Symptoms were present for>3 months.
Samples and data were also collected from 47 healthy volunteers without renal dysfunction
as controls (Table 1).
Blood collection and biochemical analysis
Venous blood was collected after overnight fasting. Because the presepsin concentration is
increased by strong agitation, samples after complete blood count measurement cannot be
used. Thus, samples were collected into EDTA-2K blood collection tubes for presepsin mea-
surement. At the time of blood sampling, five gentle inversions were performed (S1 Fig). The
blood sample was transported in a manner that prevented agitation, and the measurement was
started within 10 min after blood collection.
The estimated glomerular filtration rate (eGFR) of each participant was calculated using the
equation provided by the Japanese Society of Nephrology as follows:
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eGFRcreat (mL/min/1.73 m2) = 194 × creatinine (mg/dL)-1.094 × Age-0.287 (if female, ×
0.739)
eGFRcys (mL/min/1.73 m2) = (104 × cystatine [mg/dL]-1.019 × 0.996Age [If female, ×0.929] -
8)
GFR was categorized according to the KDIGO 2012 by eGFRcys [13].
Measurement of presepsin
Presepsin concentrations were measured with a compact automated immunoanalyzer “PATH-
FAST” (LSI Medience Corporation, Tokyo, Japan) based on a chemiluminescent enzyme
immunoassay with EDTA-whole blood.
Methods for recalculation of reference ranges
Recalculation of the reference range was performed using the nonparametric method. All val-
ues were listed in order according to the CLSI guidelines, and values of 2.5–97.5% were used as
the reference range. Excision of extremes was not performed [14].
Ethical approval
This study protocol and consent procedure were approved by the Ethics Committee of
Tokushima University Hospital (No. 2699) and performed in compliance with the Helsinki
Declaration. Written informed consent was obtained from all patients.
Table 1. Clinical characteristics of participants in the different GFR categories.
Normal G1 G2 G3 G4 G5 P value
N 47 20 26 19 11 9
age 30.8 ±10.5 40.6 ±11.2 56.7 ±12.5 61.8 ±14.9 66.0 ±13.3 66.9 ±13.6 < 0.01
male,n (%) 21 (44.7) 10 (50.0) 20 (76.9) 15 (78.9) 6 (54.5) 6 (66.6) 0.693
height (cm) 164.3 ±8.9 166.4 ±8.5 165.3 ±8.6 163.7 ±8.5 163.9 ±11.2 158.2 ±7.9 0.378
weight (kg) 58.7 ±11.6 69.3 ±15.6 61.9 ±11.7 67.6 ±14.9 62.7 ±13.9 55.8 ±9.5 0.032
Body surface area (m2) 1.634 ±0.19 1.767 ±0.21 1.501 ±0.54 1.594 ±0.50 1.677 ±0.23 1.556 ±0.14 0.217
AST (U/L) 18.0 ±6.2 23.2 ±12.7 22.9 ±8.6 24.2 ±8.0 19.1 ±6.0 21.4 ±7.6 0.420
ALT (U/L) 16.1 ±15.5 23.8 ±12.1 19.2 ±9.1 20.6 ±11.1 11.7 ±3.7 15.2 ±4.1 0.029
creatinine (mg/dL) 0.718 ±0.15 0.684 ±0.16 0.952 ±0.22 1.716 ±0.45 2.245 ±0.70 5.143 ±2.33 < 0.01
cystatine-C (mg/dL) no data 0.710 ±0.07 1.007 ±0.11 1.657 ±0.24 2.415 ±0.33 4.021 ±0.66 < 0.01
urea nitrogen (mg/dL) 13.2 ±3.2 12.4 ±3.1 15.2 ±4.1 26.4 ±6.9 36.8 ±8.0 56.7 ±20.0 < 0.01
eGFR creat (ml/min/1.73m2) 93.0 ±12.9 92.4 ±18.6 63.3 ±14.3 33.0 ±9.9 23.2 ±6.2 10.2 ±3.6 < 0.01
eGFR cys (ml/min/1.73m2) no data 114.2 ±14.8 73.7 ±7.2 40.1 ±7.4 23.9 ±3.7 11.3 ±3.3 < 0.01
white blood cell (�109/L) 5.5 ±1.2 6.4 ±2.3 6.1 ±1.6 5.5 ±1.4 5.8 ±1.8 6.5 ±2.1 0.123
hemoglobin (g/dL) 13.6 ±1.5 14.4 ±1.6 13.8 ±1.5 13.1 ±1.6 11.7 ±1.3 10.8 ±1.4 < 0.01
hematocrit (%) 41.0 ±4.0 42.6 ±4.1 40.7 ±4.0 38.4 ±4.6 35.6 ±3.5 33.1 ±3.4 < 0.01
platelets (�109/L) 247.1 ±49.4 242.1 ±64.6 245.4 ±52.1 215.3 ±43.7 353.6 ±463.9 188.2 ±43.5 0.473
Data are presented as the mean ± standard deviation, as number (%).
GFR categories: Categorized according to the KDIGO 2012 by eGFRcys.
G1: eGFRcys�90 mL/min/1.73 m2; G2: eGFRcys = 60–90 mL/min/1.73 m2; G3: eGFRcys = 30–60 mL/min/1.73 m2; G4: eGFRcys = 15–30 mL/min/1.73 m2; G5:
eGFRcys�15 mL/min/1.73 m2.
P value was calculated by one-way analysis of variance.
https://doi.org/10.1371/journal.pone.0215791.t001
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Statistical analysis
All values are shown as the mean ± standard deviation. The results were analyzed as non-
parametric variables using Mann-Whitney’s U test for comparison between two groups and
using Kruskal-Wallis tests with Bonferroni post hoc test for multiple comparisons. Correlation
was evaluated by Spearman’s correlation coefficient by a rank test. Statistical analyses were per-
formed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [15]. A P
value < 0.05 was considered to indicate significance.
Results
Comparison between normal and chronic renal failure
The presepsin levels in the chronic renal failure group (CKD G4 � G5) was significantly higher
(410.1 ± 318.9 pg/mL) than that in the normal group (97.6 ± 27.4 pg/mL) (P = 0.01) (Fig 1).
Correlation with renal functional indices
The presepsin levels were analyzed for their correlation with creatinine, eGFRcreat, cystatin-C,
and eGFRcys. The correlation coefficients were as follows: creatinine, r = 0.834; eGFRcreat,
r = 0.837; cystatin-C, r = 0.845; and eGFRcys, r = 0.879. All correlations were significant, and
presepsin levels increased with deterioration of renal function (Fig 2).
Stratified comparison in CKD patients
In patients with CKD, presepsin levels were stratified by GFR stage classified by eGFRcys (Fig
3). The presepsin levels in each group were: Normal: 97.6 ± 27.4 pg/mL, CKD G1: 100.2 ± 27.6
pg/mL, CKD G2: 129.7 ± 40.7 pg/mL, CKD G3: 208.1 ± 70.2 pg/mL, CKD G4: 320.2 ± 170.1
pg/mL, CKD G5: 712.8 ± 336.3 pg/mL.
As a result, presepsin levels showed a significant tendency to increase in the CKD G2
patient group, which is regarded as the mildly declining group, as the GFR stage increased. In
contrast, in patients with CKD G1, in which renal function was maintained, there was no sig-
nificant difference between presepsin levels in patients and control individuals.
Recalculation of reference range considering renal function
A total of 67 cases in the normal group and CKD G1 patient group were used to determine the
reference range calculated using a nonparametric method. The recalculated reference range
was 59–153 pg/mL, which was lower than the reference range of 98.3–314 pg/mL provided by
the reagent manufacturer of PATHFAST.
Discussion
Presepsin levels are affected by altered renal function and sample agitation. However, in previ-
ous studies, the effects of agitation were not considered, and the possibility of a false high level
could not be excluded.
This study, which eliminated the influence of stirring and sampling, clarified that presepsin
concentrations are strongly correlated with various renal function indices and tended to
increase with renal function deterioration.
The molecular weight of presepsin is approximately 13 kDa, which is similar to that of
cystatin-C. Presepsin levels increase and accumulate in the blood when renal function is
impaired in patients with renal disorders.
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As significant correlation was found for all indices examined in this study. Interestingly,
eGFRcreat, which is generally used as a renal function index, rather than creatinine, showed
the same correlation as creatinine. Because the presepsin level was not dependent on the indi-
vidual’s sex or age, these factors were predicted to have no significant influence on the presep-
sin value. In the stratified comparison, a significant difference was found in both eGFRcreat
and eGFRcys. However, for eGFRcys, the influence from a lower range was confirmed (S2
Fig). This was likely because cystatin C reflected kidney disorder from an earlier stage com-
pared to creatinine. We corrected the sampling to measure presepsin and analyzed the data by
using eGFRcys. Therefore, a significant false high value reflecting renal function was con-
firmed in a group of patients with early-stage CKD compared as that found by Nagata et al by
using eGFRcreat.
Although presepsin showed an increasing trend in the early stage due to the deterioration
of renal function, there was no significant difference between healthy subjects and patients in
the CKD G1 group. Thus, the CKD G1 group may be diagnosed as normal. In patients in the
CKD G2 group and higher stages, a significant increase in presepsin was observed even in
uninfected cases. Sepsis diagnosis is not based on only one biomarker, but is a comprehensive
diagnosis based on multiple markers and clinical symptoms. Presepsin levels must be carefully
interpreted to diagnosis sepsis in patients with renal impairment.
Fig 1. Presepsin levels in control and renal failure groups. Renal failure group: CKD G4+ G5.P value was calculated
using the Mann–Whitney U test.
https://doi.org/10.1371/journal.pone.0215791.g001
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Although it has been reported that presepsin is related to age and hemoglobin levels, multi-
variate analysis using these factors as explanatory variables revealed no independent causality
other than renal function (S1 Table). It is possible that renal clearance was decreased by the
influence of aging or renal anemia may have influenced presepsin levels, but no direct causal
relationship was observed.
Additionally, false high values of presepsin arising due to vigorous agitation of the blood
samples have been reported, preventing accurate clinical assessment. Mechanical stimuli such
as agitation lead to the formation of macromolecular complexes, which reacts with the anti-
presepsin antibody in the reagent in a larger molecular weight fraction. Although the false
high value is considered to be due to cross-reaction with this polymer complex, the mechanism
of complex formation has not been clarified. There are no efficient methods other than avoid-
ing agitation of the sample at the time of blood collection/delivery to prevent these effects,
necessitating extreme caution. Although doctors and nurses collect blood at the bedside with
Fig 2. Correlation between presepsin values and renal function index. P value was calculated with Spearman’s correlation coefficient
test.eGFRcreat (mL/min/1.73 m2) = 194 × creatinine (mg/dL)-1.094 × Age-0.287 (if female, × 0.739) eGFRcys (mL/min/1.73 m2) =
(104 × cystatine [mg/dL]-1.019 × 0.996Age [If female, ×0.929]-8).
https://doi.org/10.1371/journal.pone.0215791.g002
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caution, fluctuations at the pre-measurement stage can be large, affecting the reliability of the
results. Therefore, it is essential to educate clinical practitioners regarding specimen collection.
In this study, recalculation of the reference range using data from the CKD G1 group and
normal group indicated remarkably low values 59–153 pg/mL, which were half of the reference
range currently in use. The sample group used to calculate the reference range by the reagent
manufacturer did not consider the effects of renal function or agitation, and it is likely that
these false high values were included. Therefore, this sample group may not be appropriate for
calculating the reference range. In contrast, the sample group used for recalculation in this
study excluded false high value cases caused by renal function and agitation, making it a more
useful index.
The new reference range obtained in this study can be used for the early diagnosis of sepsis
in patients with normal kidney function. However, the new reference range obtained in this
study did not meet the requirement for 120 cases recommended by CLSI guidelines and may
not be sufficient evidence for establishing a new reference range [14]. Further larger studies
are needed to establish a more reliable reference range.
This study had some limitations. First, the presence or absence of an infectious disease
could not be completely excluded, as this factor was based on the judgment of the physician.
Second, in the sample group examined in this study, there was an age difference between the
normal group and CKD patient group. Although age was not an independent variable, normal
groups with no difference in age should be considered as the control group.
In conclusion, by excluding the effect of stirring during sampling, our study demonstrated
that presepsin levels exhibit an increasing trend as GFR decreases. Currently, the false high val-
ues obtained using the standard reference range are largely ignored. Therefore, using the
Fig 3. Plot of presepsin concentrations in controls or patients with chronic kidney disease vs GFR stage classified
by eGFRcys. P value was calculated by Kruskal-Wallis one-way analysis of variance. P value adjustment was calculated
using the Bonferroni method.
https://doi.org/10.1371/journal.pone.0215791.g003
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newly recalculated reference range, which excludes the effects of renal function and agitation,
may improve the efficiency in sepsis diagnosis, particularly in the early stage. However, we rec-
ommend larger studies to confirm these findings and support alternate reference ranges.
Supporting information
S1 Fig. Effect of agitation on presepsin measurements. P value was calculated using paired t
test.
(PDF)
S2 Fig. Plot of presepsin concentrations in patients with chronic kidney disease vs GFR
stage classified by eGFRcreat. P value was calculated by Kruskal-Wallis one-way analysis of
variance.
P value adjustment was calculated using the Bonferroni method.
(PDF)
S1 Table. Univariable analysis and multivariate linear regression analysis of characteristics
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